Patents by Inventor Ellen Wagner

Ellen Wagner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High affinity engineered T-cell receptors targeting cmv infected cells
    Patent number: 12649772
    Abstract: Provided herein are engineered T-celi receptors (TCRs) having nanomoiar affinity for the immuno-dominant pp65 peptide residing between residues 495-503 (NLV) in complex with HLA-A2*02:01. The TCRs may be membrane-hound TCRs, soluble TCRs, chimeric TCRs, or chimeric antigen receptors. Also provided are methods of using the engineered TCRs to treat diseases, monitor disease progression, monitor vaccine efficacy, and detecting NLV/A2 presentation on the surface of cells.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: June 9, 2026
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer A. Maynard, Ellen Wagner, Ahlam N. Qerqez, Annalee Nguyen
  • HIGH AFFINITY ENGINEERED T-CELL RECEPTORS TARGETING CMV INFECTED CELLS
    Publication number: 20220144916
    Abstract: Provided herein are engineered T-cell receptors (TCRs) having nanomolar affinity for the immuno-dominant pp65 peptide residing between residues 495-503 (NLV) in complex with HLA-A2*02:01. The TCRs may be membrane-hound TCRs, soluble TCRs, chimeric TCRs, or chimeric antigen receptors. Also provided are methods of using the engineered TCRs to treat diseases, monitor disease progression, monitor vaccine efficacy, and detecting NLV/A2 presentation on the surface of cells.
    Type: Application
    Filed: February 12, 2020
    Publication date: May 12, 2022
    Inventors: Jennifer A. MAYNARD, Ellen WAGNER, Ahlam N. QERQEZ, Annalee NGUYEN
  • Bispecific pertussis antibodies
    Patent number: 10538579
    Abstract: The present invention relates, in part, to bispecific antibodies that bind the pertussis toxin protein. The present invention further relates to the use of the bispecific antibodies for the prevention and treatment of Bordetella pertussis infections.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: January 21, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer Maynard, Ellen Wagner
  • Humanized pertussis antibodies and used thereof
    Patent number: 10526400
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 7, 2020
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • HUMANIZED PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20180362621
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Application
    Filed: June 25, 2018
    Publication date: December 20, 2018
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • Humanized pertussis antibodies and uses thereof
    Patent number: 10035846
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 31, 2018
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • BISPECIFIC PERTUSSIS ANTIBODIES
    Publication number: 20180118817
    Abstract: The present invention relates, in part, to bispecific antibodies that bind the pertussis toxin protein. The present invention further relates to the use of the bispecific antibodies for the prevention and treatment of Bordetella pertussis infections.
    Type: Application
    Filed: August 15, 2017
    Publication date: May 3, 2018
    Inventors: Jennifer MAYNARD, Ellen WAGNER
  • HUMANIZED PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20170066816
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Application
    Filed: November 18, 2016
    Publication date: March 9, 2017
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • Humanized pertussis antibodies and uses thereof
    Patent number: 9512204
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: December 6, 2016
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner